Atara Biotherapeutics (ATRA) Downgraded by BidaskClub to “Buy”
BidaskClub lowered shares of Atara Biotherapeutics (NASDAQ:ATRA) from a strong-buy rating to a buy rating in a research note issued to investors on Thursday morning.
Several other research analysts have also weighed in on ATRA. JMP Securities lowered Atara Biotherapeutics from an outperform rating to a market perform rating in a report on Wednesday, February 28th. Zacks Investment Research lowered Atara Biotherapeutics from a hold rating to a sell rating in a report on Tuesday, February 6th. ValuEngine upgraded Atara Biotherapeutics from a sell rating to a hold rating in a report on Friday, December 29th. Canaccord Genuity restated a buy rating on shares of Atara Biotherapeutics in a report on Thursday, November 9th. Finally, Citigroup lowered Atara Biotherapeutics from a neutral rating to a sell rating in a report on Thursday, February 15th. One research analyst has rated the stock with a sell rating, four have given a hold rating and five have assigned a buy rating to the stock. The stock has an average rating of Hold and an average target price of $30.60.
Atara Biotherapeutics (ATRA) opened at $39.40 on Thursday. Atara Biotherapeutics has a twelve month low of $11.80 and a twelve month high of $49.90.
Institutional investors have recently modified their holdings of the company. SG Americas Securities LLC bought a new stake in shares of Atara Biotherapeutics in the third quarter valued at about $142,000. Voya Investment Management LLC lifted its holdings in shares of Atara Biotherapeutics by 16.2% in the second quarter. Voya Investment Management LLC now owns 11,813 shares of the biotechnology company’s stock valued at $165,000 after purchasing an additional 1,651 shares in the last quarter. Russell Investments Group Ltd. bought a new stake in Atara Biotherapeutics during the third quarter worth about $170,000. MetLife Investment Advisors LLC bought a new stake in Atara Biotherapeutics during the fourth quarter worth about $217,000. Finally, The Manufacturers Life Insurance Company raised its holdings in Atara Biotherapeutics by 7.2% during the second quarter. The Manufacturers Life Insurance Company now owns 20,377 shares of the biotechnology company’s stock worth $285,000 after acquiring an additional 1,369 shares in the last quarter. Institutional investors own 75.92% of the company’s stock.
TRADEMARK VIOLATION WARNING: This report was first published by Daily Political and is owned by of Daily Political. If you are reading this report on another website, it was illegally stolen and reposted in violation of United States and international trademark and copyright laws. The legal version of this report can be read at https://www.dailypolitical.com/2018/03/05/atara-biotherapeutics-atra-downgraded-by-bidaskclub-to-buy.html.
Atara Biotherapeutics Company Profile
Atara Biotherapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies for patients with severe and life-threatening diseases. The Company operates through the business of developing and commercializing therapeutics segment. The Company is focused on developing allogeneic or third-party derived antigen-specific T-cells.
Receive News & Ratings for Atara Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atara Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.